Previous close | 19.00 |
Open | 10.95 |
Bid | 9.60 |
Ask | 11.10 |
Strike | 133.00 |
Expiry date | 2024-06-28 |
Day's range | 9.15 - 10.95 |
Contract range | N/A |
Volume | |
Open interest | 21 |
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality...
Moderna revealed its combination flu/COVID vaccine performed better than the two shots independently.